DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Return
12.76%
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$332M
(+6.1%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-14.52%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
65
Reduced
45
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$66.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 4 |
Baxter International
BAX
|
$57.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$28.4M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Rithm Capital
RITM
$6.67B
| $232K | ﹤0.01% |
+20,824
| New | +$232K |
|
302
American Vanguard Corp
AVD
$159M
| $232K | ﹤0.01% |
+17,931
| New | +$232K |
|
303
Exponent
EXPO
$3.66B
| $229K | ﹤0.01% |
+2,774
| New | +$229K |
|
304
Fastenal
FAST
$55B
| $229K | ﹤0.01% |
+5,934
| New | +$229K |
|
305
Customers Bancorp
CUBI
$2.16B
| $228K | ﹤0.01% |
4,297
-14
| -0.3% | -$743 |
|
306
Supernus Pharmaceuticals
SUPN
$2.58B
| $227K | ﹤0.01% |
6,654
-5,352
| -45% | -$183K |
|
307
Woodward
WWD
$14.2B
| $225K | ﹤0.01% |
1,463
-2,147
| -59% | -$331K |
|
308
Dyne Therapeutics
DYN
$2.02B
| $225K | ﹤0.01% |
+7,940
| New | +$225K |
|
309
Veracyte
VCYT
$2.53B
| $222K | ﹤0.01% |
+10,011
| New | +$222K |
|
|
LTC
310
LTC Properties
LTC
$1.69B
| $222K | ﹤0.01% |
+6,818
| New | +$222K |
|
311
Warrior Met Coal
HCC
$3.09B
| $219K | ﹤0.01% |
+3,600
| New | +$219K |
|
312
MetLife
MET
$53.4B
| $218K | ﹤0.01% |
+2,947
| New | +$218K |
|
313
Harrow
HROW
$1.35B
| $216K | ﹤0.01% |
+16,342
| New | +$216K |
|
|
WINT
314
DELISTED
Windtree Therapeutics
WINT
| $215K | ﹤0.01% |
+676
| New | +$215K |
|
315
Kratos Defense & Security Solutions
KTOS
$10.6B
| $213K | ﹤0.01% |
+11,577
| New | +$213K |
|
316
Standard BioTools
LAB
$493M
| $212K | ﹤0.01% |
+78,090
| New | +$212K |
|
317
SentinelOne
S
$6.14B
| $210K | ﹤0.01% |
+9,023
| New | +$210K |
|
318
CarMax
KMX
$9.11B
| $210K | ﹤0.01% |
+2,407
| New | +$210K |
|
319
Adaptive Biotechnologies
ADPT
$1.94B
| $210K | ﹤0.01% |
+65,287
| New | +$210K |
|
320
SLR Investment Corp
SLRC
$911M
| $209K | ﹤0.01% |
+13,589
| New | +$209K |
|
321
Exelixis
EXEL
$10.1B
| $208K | ﹤0.01% |
8,780
+380
| +5% | +$9.02K |
|
|
LBPH
322
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $208K | ﹤0.01% |
+9,624
| New | +$208K |
|
323
Xerox
XRX
$495M
| $208K | ﹤0.01% |
+11,607
| New | +$208K |
|
|
DHC
324
Diversified Healthcare Trust
DHC
$937M
| $207K | ﹤0.01% |
+84,168
| New | +$207K |
|
325
Motorola Solutions
MSI
$79.4B
| $206K | ﹤0.01% |
580
-743
| -56% | -$264K |
|